|
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Bundle
Looking to determine the intrinsic value of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd? Our (603707SS) DCF Calculator integrates real-world data with comprehensive customization options, enabling you to refine forecasts and enhance your investment decisions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,914.9 | 3,686.7 | 3,712.7 | 3,931.4 | 3,923.6 | 4,246.1 | 4,595.0 | 4,972.7 | 5,381.4 | 5,823.7 |
| Revenue Growth, % | 0 | 26.48 | 0.70599 | 5.89 | -0.19844 | 8.22 | 8.22 | 8.22 | 8.22 | 8.22 |
| EBITDA | 1,057.7 | 1,387.4 | 1,363.1 | -57.8 | 1,241.5 | 1,195.7 | 1,294.0 | 1,400.4 | 1,515.5 | 1,640.0 |
| EBITDA, % | 36.29 | 37.63 | 36.71 | -1.47 | 31.64 | 28.16 | 28.16 | 28.16 | 28.16 | 28.16 |
| Depreciation | 84.8 | 93.4 | 139.7 | 154.2 | 174.9 | 149.3 | 161.6 | 174.9 | 189.3 | 204.8 |
| Depreciation, % | 2.91 | 2.53 | 3.76 | 3.92 | 4.46 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| EBIT | 972.9 | 1,294.0 | 1,223.4 | -212.1 | 1,066.7 | 1,046.4 | 1,132.4 | 1,225.5 | 1,326.2 | 1,435.2 |
| EBIT, % | 33.38 | 35.1 | 32.95 | -5.39 | 27.19 | 24.64 | 24.64 | 24.64 | 24.64 | 24.64 |
| Total Cash | 1,339.3 | 918.4 | 1,389.8 | 1,891.8 | 2,079.8 | 1,778.4 | 1,924.6 | 2,082.8 | 2,254.0 | 2,439.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 788.1 | 897.8 | 974.1 | 1,002.6 | 1,193.5 | 1,134.1 | 1,227.3 | 1,328.2 | 1,437.3 | 1,555.5 |
| Account Receivables, % | 27.04 | 24.35 | 26.24 | 25.5 | 30.42 | 26.71 | 26.71 | 26.71 | 26.71 | 26.71 |
| Inventories | 4,457.4 | 4,894.2 | 5,615.6 | 4,158.3 | 3,675.0 | 4,192.3 | 4,536.8 | 4,909.7 | 5,313.2 | 5,749.9 |
| Inventories, % | 152.92 | 132.75 | 151.25 | 105.77 | 93.66 | 98.73 | 98.73 | 98.73 | 98.73 | 98.73 |
| Accounts Payable | 362.6 | 458.9 | 505.1 | 537.7 | 495.7 | 550.3 | 595.5 | 644.5 | 697.5 | 754.8 |
| Accounts Payable, % | 12.44 | 12.45 | 13.61 | 13.68 | 12.63 | 12.96 | 12.96 | 12.96 | 12.96 | 12.96 |
| Capital Expenditure | -294.4 | -440.8 | -470.1 | -419.1 | -506.8 | -495.0 | -535.7 | -579.7 | -627.4 | -679.0 |
| Capital Expenditure, % | -10.1 | -11.96 | -12.66 | -10.66 | -12.92 | -11.66 | -11.66 | -11.66 | -11.66 | -11.66 |
| Tax Rate, % | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 | 16.72 |
| EBITAT | 857.5 | 1,138.7 | 1,125.8 | -136.3 | 888.3 | 870.0 | 941.5 | 1,018.9 | 1,102.6 | 1,193.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4,235.0 | 341.2 | 44.0 | 1,060.4 | 806.6 | 121.1 | 174.9 | 189.2 | 204.8 | 221.6 |
| WACC, % | 6.53 | 6.53 | 6.54 | 6.44 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 745.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 230 | |||||||||
| Terminal Value | 9,178 | |||||||||
| Present Terminal Value | 6,695 | |||||||||
| Enterprise Value | 7,440 | |||||||||
| Net Debt | 1,040 | |||||||||
| Equity Value | 6,400 | |||||||||
| Diluted Shares Outstanding, MM | 1,652 | |||||||||
| Equity Value Per Share | 3.87 |
Benefits You Will Receive
- Authentic Financial Data for Nanjing King-Friend (603707SS): Access historical and projected figures for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Dynamic computation of intrinsic value and NPV.
- Scenario Modeling: Explore various scenarios to assess Nanjing King-Friend’s future performance.
- User-Friendly Interface: Designed for professionals, yet easy for newcomers to navigate.
Key Features
- Comprehensive Data: Access to Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd’s historical financial records and pre-filled forecasts.
- Customizable Parameters: Adjust inputs such as WACC, tax rates, revenue growth, and EBITDA margins.
- Real-Time Valuation: Instantly view recalculated intrinsic value for Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS).
- Interactive Visual Displays: Dashboard graphics illustrate valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Functions
- Download the Template: Gain immediate access to the Excel-based King-Friend DCF Calculator for (603707SS).
- Enter Your Assumptions: Modify the yellow-highlighted cells to input growth rates, WACC, profit margins, and other parameters.
- Instant Results: The model automatically refreshes to reflect the intrinsic value of Nanjing King-Friend.
- Explore Scenarios: Test various assumptions to see how they impact potential valuations.
- Review and Decide: Leverage the findings to inform your investment decisions or financial assessments.
Why Choose This Calculator for Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses for comprehensive evaluations.
- Adjustable Parameters: Modify the yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Nanjing King-Friend.
- Loaded with Data: Comes with historical and projected data for reliable analysis starting points.
- Expert-Level Design: Perfect for financial analysts, investors, and business consultants in the pharmaceutical sector.
Who Can Benefit from This Product?
- Institutional Investors: Develop comprehensive and dependable valuation models for investment analysis of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS).
- Corporate Finance Departments: Evaluate valuation scenarios to support strategic decision-making within the organization.
- Financial Consultants and Advisors: Equip clients with precise valuation insights related to Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS).
- Academics and Students: Utilize real-world financial data for practical applications in teaching and learning financial modeling.
- Health and Pharma Enthusiasts: Gain insights into how the pharmaceutical industry values companies like Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS).
What the Template Contains
- Historical Data: Covers Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd's (603707SS) previous financials and foundational forecasts.
- DCF and Levered DCF Models: Comprehensive templates for calculating the intrinsic value of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707SS).
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust key parameters such as growth rates, EBITDA percentages, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete overview of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd's (603707SS) financial performance.
- Interactive Dashboard: Dynamically visualize the valuation outcomes and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.